Abstracts tagged "Osteoarthritis"

Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
David Hunter¹, Tuhina Neogi², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi², Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ²Boston University School of Medicine, Boston, MA, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1657 • ACR Convergence 2020
Do Comorbidities Limit Improvement in Pain and Physical Function After Total Knee Arthroplasty in Patients with Knee Osteoarthritis?
Lauren King¹, Esther Waugh¹, Allyson Jones², Deborah Marshall³ and Gillian Hawker⁴, ¹University of Toronto, Toronto, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with knee osteoarthritis (OA) are increasingly living with multiple comorbid conditions. The presence of comorbidities has been associated with having worse OA symptoms…
Abstract Number: 0150 • ACR Convergence 2020
The Preparation Experience for Total Knee Arthroplasty of Patients with Osteoarthritis: A Cross-Sectional Survey
Aretina Leung¹, Geyanne Lui², Susan Goodman³, Lisa Mandl⁴, Peter Sculco⁵, Mark Figgie³ and Iris Navarro-Millan¹, ¹Weill Cornell Medicine, New York, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: We previously identified several barriers and facilitators of exercise before total knee arthroplasty (TKA) in a small qualitative study, as well as the existence…
Abstract Number: 0700 • ACR Convergence 2020
Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Mandar Dave¹, Abul Islam², Akshat Parekh³, Jay Patel⁴, Arushi Chawla⁵ and Ashok Amin⁶, ¹Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, ²Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh, ³Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, ⁴Northeast Ohio Medical University, Rootstown, OH, ⁵Gujarat Forensic Science University, Gujarat, India, ⁶Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Human OA-affected cartilage does not show the cardinal signs of inflammation (redness and swelling with heat and pain—rubor et tumor cum calore et dolor) because…
Abstract Number: 1100 • ACR Convergence 2020
The Hand Osteoarthritis Registry of New York University: Impacts of Gender and Obesity
Fernando Bomfim¹, Shannon Chen², Stephen Zak³, Taylor Jazrawi², Vivienne Qie³, Benjamin Plotz² and Jonathan Samuels⁴, ¹New York University, Department of Medicine, Division of Rheumatology, Millburn, NJ, ²NYU Langone Health, New York, ³NYU Langone Health, New York, NY, ⁴NYU Langone, Rye Brook, NY
Background/Purpose: Hand osteoarthritis (HOA) data is often obtained from large knee OA cohorts. Targeted HOA cohorts in Europe have shed light on this disease, but…
Abstract Number: 1116 • ACR Convergence 2020
Magnetic Resonance Imaging Structural Changes Correlated with Knee Extension: Data from the Osteoarthritis Initiative
T Mark Campbell¹, Guy Trudel² and Dennis McGonagle³, ¹Elisabeth Bruyère Hospital, Ottawa, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Knee OA is often accompanied by loss of passive extension, termed a flexion contracture (FC), resulting in worse clinical outcomes. To our knowledge, MRI-based…
Abstract Number: 1482 • ACR Convergence 2020
Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis
John Carrino¹, Timothy McAlindon², Eric Vignon³, Mark Brown⁴, Aimee Burr⁴, Robert Fountaine⁴, Glenn Pixton⁵, Lars Viktrup⁶, Christine West⁷ and Kenneth Verburg⁸, ¹Hospital for Special Surgery, Hackensack, NJ, ²Tufts Medical Center, Boston, MA, ³Université Claude Bernard Lyon 1, Pierre Benite, France, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: Tanezumab, a monoclonal antibody that inhibits nerve growth factor, has been shown effective in the management of osteoarthritis (OA) pain.1,2 Due to the potential…
Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Tuhina Neogi¹, David Hunter², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi¹, Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Boston University School of Medicine, Boston, MA, ²Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1658 • ACR Convergence 2020
Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis
Marieke Loef¹, Rob van der Geest¹, Hildo Lamb¹, Renée de Mutsert¹, Frits Rosendaal¹ and Margreet Kloppenburg¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Obesity-related metabolic dysregulation may lead to atherosclerotic vascular changes. It has been hypothesized that a compromised blood flow may cause detrimental changes to the…
Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Benjamin Hsu¹, Jennifer Visich ², Mark Genovese ³, Kimberly Walter ², Mahru An ⁴, Remi-Martin Laberge ⁴ and Jamie Dananberg ⁴, ¹Unity Biotechnology, Brisbane, ²Unity Biotechnology, Brisbane, California, ³Stanford University, Stanford, CA, ⁴Unity Biotechnology, Brisbane, CA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…
Abstract Number: 1129 • 2019 ACR/ARP Annual Meeting
Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Jamie Huizinga¹, Elizabeth Stanley ¹, Shuang Song ¹, James Sullivan ², Jeffrey Katz ³ and Elena Losina ⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital/Harvard Medical School, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Symptomatic knee OA affects 14 million adults in the US. Recent estimates suggest that about 40% of people with knee OA are taking prescription…
Abstract Number: 1317 • 2019 ACR/ARP Annual Meeting
Frail Patients Have Worse Function After Total Knee Replacement
Lisa Mandl¹, Charles Cornell ¹, Michael Cross ¹, Alejandro Gonzalez Della Valle ¹, Mark Figgie ¹, Seth Jerabek ¹, Marianna Frey ², John Roberts IV ³, Justin Do ³, Mayu Sasaki ³, Nathaniel Hupert ⁴, Jackie Finik ³ and Steven Magid ¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ²Hospital for Special Surgery, New York, NY, New York, ³Hospital for Special Surgery, New York, NY, New York, NY, ⁴Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: To determine whether frailty is associated with patient outcomes 1 year after total knee replacement (TKR).Methods: Patients ≥65yo scheduled for elective primary TKR for…
Abstract Number: 1968 • 2019 ACR/ARP Annual Meeting
A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis
Eloi Franco-Trepat¹, Ana Alonso-Pérez ¹, Maria Guillán-Fresco ¹, Alberto Jorge-Mora ², Ana Lois Iglesias ³, Oreste Gualillo ⁴ and Rodolfo Gómez ¹, ¹Institute IDIS - Musculoskeletal Pathology Group, Santiago de Compostela, Spain, ²Institute IDIS - Musculoskeletal Pathology Group, Santiago de Compostela, ³Institute IDIS - Musculoskeletal Pathology Group, Santiago de Compostela, Galicia, Spain, ⁴Institute IDIS - NEIRID Lab - SERGAS, Santiago de Compostela, Spain
Background/Purpose: Rheumatic diseases, also known as musculoskeletal pathologies, are steadily rising their prevalence. This worldwide phenomenon is depriving our society of their life quality and…
Abstract Number: 2057 • 2019 ACR/ARP Annual Meeting
Cross-sectional Associations of Multiple Joint Osteoarthritis in the Osteoarthritis Initiative
Charles Eaton¹, Mary Roberts ², Jeffrey Driban ³, Michael Nevitt ⁴, Jeffrey Duryea ⁵ and Timothy McAlindon ⁶, ¹Warren Alpert Medical School of Brown University, Pawtucket, RI, ²Center for Primary Care and Prevention, Pawtucket, ³Tufts Medical Center, Boston, ⁴University of California at San Francisco, San Francisco, CA, ⁵Harvard Medical School Department of Radiology Brigham and Women's Hospital, Boston, MA, ⁶Tufts Medical Center, Boston, MA
Background/Purpose: Multiple joint osteoarthritis (MJOA) may represent a unique phenotype of osteoarthritis related to systemic factors associated with pathologic aging. We tested the hypothesis that metabolic…
Abstract Number: 2189 • 2019 ACR/ARP Annual Meeting
Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population
Marieke Loef¹, Féline PB Kroon ¹, Stephan Böhringer ¹, Frits R Rosendaal ¹ and Margreet Kloppenburg ¹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Background/Purpose: The Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire is a widely used patient-reported outcome tool, developed to evaluate short- and long-term knee symptoms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].